Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Donidalorsen in Hereditary Angioedema
NCT04307381Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Mar 2020
- Primary completion
- Jan 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 2 trial of donidalorsen in hereditary angioedema (HAE), sponsored by Ionis Pharmaceuticals. Started Mar 2020; status: completed.
02
Drugs
donidalorsen
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04307381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04307381.